1. Sci Rep. 2020 Mar 10;10(1):4449. doi: 10.1038/s41598-020-61265-y.

Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by 
protein CK-1δ kinase inhibitor treatment.

Martínez-González L(1), Rodríguez-Cueto C(2)(3)(4), Cabezudo D(2), Bartolomé 
F(4)(5), Andrés-Benito P(4)(6)(7), Ferrer I(4)(6)(7), Gil C(1)(4), 
Martín-Requero Á(1)(4), Fernández-Ruiz J(2)(3)(4), Martínez A(8)(9), de Lago 
E(10)(11)(12).

Author information:
(1)Centro de Investigaciones Biológicas Margarita Salas-CSIC, Ramiro de Maeztu 
9, 28040, Madrid, Spain.
(2)Instituto Universitario de Investigación en Neuroquímica, Departamento de 
Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, 
Madrid, Spain.
(3)Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
(4)Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas 
(CIBERNED), Madrid, Spain.
(5)Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041, 
Madrid, Spain.
(6)Department of Pathology and Experimental Therapeutics, University of 
Barcelona, Hospitalet de Llobregat, Barcelona, Spain.
(7)Bellvitge University Hospital, IDIBELL (Bellvitge Biomedical Research 
Centre), Hospitalet de Llobregat, Barcelona, Spain.
(8)Centro de Investigaciones Biológicas Margarita Salas-CSIC, Ramiro de Maeztu 
9, 28040, Madrid, Spain. ana.martinez@csic.es.
(9)Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas 
(CIBERNED), Madrid, Spain. ana.martinez@csic.es.
(10)Instituto Universitario de Investigación en Neuroquímica, Departamento de 
Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, 
Madrid, Spain. elagofem@ucm.es.
(11)Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. 
elagofem@ucm.es.
(12)Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas 
(CIBERNED), Madrid, Spain. elagofem@ucm.es.

Pathogenesis of amyotrophic lateral sclerosis (ALS), a devastating disease where 
no treatment exists, involves the compartmentalization of the nuclear protein 
TDP-43 (TAR DNA-binding protein 43) in the cytoplasm which is promoted by its 
aberrant phosphorylation and others posttranslational modifications. Recently, 
it was reported that CK-1δ (protein casein kinase-1δ) is able to phosphorylate 
TDP-43. Here, the preclinical efficacy of a benzothiazole-based CK-1δ inhibitor 
IGS-2.7, both in a TDP-43 (A315T) transgenic mouse and in a human cell-based 
model of ALS, is shown. Treatment with IGS-2.7 produces a significant 
preservation of motor neurons in the anterior horn at lumbar level, a decrease 
in both astroglial and microglial reactivity in this area, and in TDP-43 
phosphorylation in spinal cord samples. Furthermore, the recovery of TDP-43 
homeostasis (phosphorylation and localization) in a human-based cell model from 
ALS patients after treatment with IGS-2.7 is also reported. Moreover, we have 
shown a trend to increase in CK-1δ mRNA in spinal cord and significantly in 
frontal cortex of sALS cases. All these data show for the first time the in vivo 
modulation of TDP-43 toxicity by CK-1δ inhibition with IGS-2.7, which may 
explain the benefits in the preservation of spinal motor neurons and point to 
the relevance of CK-1δ inhibitors in a future disease-modifying treatment for 
ALS.

DOI: 10.1038/s41598-020-61265-y
PMCID: PMC7064575
PMID: 32157143 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no competing interests.